Post

New research · Ophthalmology
The British journal of ophthalmology · 13h
StudyThe British journal of ophthalmology · 2026

Efficacy of lenadogene nolparvovec gene therapy versus idebenone in Leber hereditary optic neuropathy due to the m.11778G>A MT-ND4 variant: two matching adjusted indirect comparisons.

Patrick Yu-Wai-Man, Nancy J Newman, Valerio Carelli … José-Alain Sahel
Read paper
OphthalmologyStudy

Gene therapy linked to higher clinically relevant visual recovery at 24 months than idebenone

Efficacy of lenadogene nolparvovec gene therapy versus idebenone in Leber hereditary optic neuropathy due to the m.11778G>A MT-ND4 variant: two matching adjusted indirect comparisons.

Patrick Yu-Wai-Man … José-Alain Sahel
The British journal of ophthalmology · 2026
Background

Lenadogene nolparvovec is an intravitreal gene therapy for patients with Leber hereditary optic neuropathy (leber hereditary optic neuropathy) carrying the m.11778G>A MT-ND4 variant.

Purpose

To estimate the relative effects of both treatments, we performed two matching adjusted indirect comparisons (matching adjusted indirect comparisons) between idebenone aggregated data from the LEROS study and expanded access programme (expanded access programme), and lenadogene nolparvovec individual data from the REFLECT study (bilateral treatment).

Methods

Matching covariates included age at disease onset, sex, baseline best-corrected visual acuity (BCVA), and time from vision loss to treatment.

Results

gene therapy patients recovered meaningful vision far more often than idebenone patients

OR by subgroup · 95% CI
null = 1
idebenone
2.78
5% for lenadogene nolparvovec
3.59
More results

No statistically significant difference was observed for time to initial clinically relevant recovery and change from baseline BCVA at 24 months.

For the matching adjusted indirect comparisons expanded access programme versus REFLECT, there was a low overlap between the two populations related to a difference in the time from vision loss to treatment.

More results

In a post hoc sensitivity analysis comparing expanded access programme to RESCUE data (effective sample size: 33), clinically relevant recovery was 39.0% for idebenone versus 69.5% for lenadogene nolparvovec (OR=3.59, 95% CI 1.42 to 9.06; p=0.011).

“
Conclusion

The two matching adjusted indirect comparisons demonstrated a clinically meaningful higher visual recovery at 24 months with lenadogene nolparvovec than with idebenone in patients with leber hereditary optic neuropathy due to the m.11778G>A MT-ND4 variant.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment